{"id":"NCT05458856","sponsor":"Ipsen","briefTitle":"Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate","officialTitle":"An Open-label, Multicentre, Single Arm Study to Assess the Efficacy and Safety of Triptorelin 6-month Formulation Administered Subcutaneously in Participants With Locally Advanced and/or Metastatic Prostate Cancer Previously Treated and Castrated With a GnRH Analogue","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-08-30","primaryCompletion":"2024-07-08","completion":"2024-07-08","firstPosted":"2022-07-14","resultsPosted":"2025-07-23","lastUpdate":"2025-07-25"},"enrollment":147,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Triptorelin embonate 22.5 mg","otherNames":["Decapeptyl"]}],"arms":[{"label":"Triptorelin embonate","type":"EXPERIMENTAL"}],"summary":"The aim of the study is to determine if triptorelin formulated for use every 6 months (given twice during the study) is effective and safe for when given by injection under the skin for the treatment of adult males with cancer in the prostate.","primaryOutcome":{"measure":"Percentage of Participants Who Maintained Castrate Levels of Serum Testosterone During the Study","timeFrame":"Up to Day 337","effectByArm":[{"arm":"Triptorelin Embonate 22.5 mg","deltaMin":95,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":15},"locations":{"siteCount":39,"countries":["Belgium","Czechia","France","Germany","Lithuania","Netherlands","Spain"]},"refs":{"pmids":[],"seeAlso":["https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2025/07/04145025/D-FR-52014-245_Lay-Summary_Final_04Jul2025.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":145},"commonTop":["Hot flush","Hypertension","Fall","Fatigue"]}}